GSK以高达6.9亿美元的价格向Alfasigma出售其试验性肝脏药物直线肝脏的全球权利。 GSK sells global rights to its experimental liver drug linerixibat to Alfasigma for up to $690 million.

GSK已将其实验性药物linerixibat的全球权利授权给意大利Alfasigma，该药物用于治疗原发性胆管炎引起的严重瘙痒，交易金额高达6.9亿美元。 GSK has licensed global rights to its experimental drug linerixibat, which treats severe itching from primary biliary cholangitis, to Italy’s Alfasigma in a deal worth up to $690 million. 艾尔法西格玛将在全球范围内开发,制造和商业化该药物,并预先向GSK支付3亿美元,在美国FDA批准后可能支付1亿美元的额外款项,欧盟和英国批准后支付2000万美元,销售里程碑高达2.7亿美元,并分层双位数的版权使用费. Alfasigma will develop, manufacture, and commercialize the drug worldwide, paying GSK $300 million upfront, with potential additional payments of $100 million upon U.S. FDA approval, $20 million for EU and UK approval, up to $270 million in sales milestones, and tiered double-digit royalties. 该药物尚未在美国、欧盟和日本获得核准,在美国、欧盟和日本具有无主药物地位,在取得积极的第三阶段试验结果后,目前正在审查中。 The drug, not yet approved anywhere, holds orphan drug status in the U.S., EU, and Japan and is under review following positive phase III trial results. 协议于3月24日结束, 让GSK能专注于其他肝病治疗。 The deal closes March 24, allowing GSK to focus on other liver disease treatments.